SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS	Blood Protein Disorders, CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, acute biphenotypic leukemia, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, monoclonal gammopathy, myeloid leukemia, neoplasm, plasma cell neoplasm, skin disorder, skin neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 1	2026-02-12		NCT06325748

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Senti Biosciences	2

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Colorado Blood Cancer Institute	Denver	United States	178
Mayo Clinic	Jacksonville	United States	122
MD Anderson Cancer Center	Houston	United States	589
Methodist Healthcare	San Antonio	United States	5
Peter MacCallum Cancer Center	Melbourne	Australia	12
Royal Prince Alfred Hospital	Camperdown	Australia	83
TriStar Bone Marrow Transplant	Nashville	United States	8
UCLA Medical Center	Los Angeles	United States	42